Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnostykaFRA:7JS +0.10%26 Operating Cash Flow per Share is €3.86 as of Mar. 2026. GuruFocus rates FRA:7JS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 157 Medical Diagnostics & Research companies, Diagnostyka ranks better than 65.61% on this metric.
Diagnostyka's operating cash flow per share for the
three
months ended in Mar. 2026 was €0.96.
Diagnostyka's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.86.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Diagnostyka was 25.20% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 24.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Diagnostyka's Operating Cash Flow per Share or its related term are showing as below:
FRA:7JS'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -17.5 Med: 3.65 Max: 24.8
Current: 24.8
During the past 5 years, Diagnostyka's highest 3-Year average Operating Cash Flow per Share Growth Rate was 24.80% per year. The lowest was -17.50% per year. And the median was 3.65% per year.
FRA:7JS's 3-Year OCF Growth Rate is ranked better than 65.61% of 157
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs FRA:7JS: 24.80
Diagnostyka Operating Cash Flow per Share Related Terms
Diagnostyka Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Diagnostyka's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7JS vs TMO, DHR, NTRA: Operating Cash Flow per Share Comparison
For the Diagnostics & Research subindustry, Diagnostyka's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka Price-to-Operating-Cash-Flow vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Diagnostyka's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of €3.86 mean?
Diagnostyka (FRA:7JS) has a Operating Cash Flow per Share of €3.86 as of Mar. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Diagnostyka and its competitors. According to the industry distribution chart, Diagnostyka ranks #54 out of 157 companies in the Medical Diagnostics & Research industry, placing it in the top 34.4%.
Is Diagnostyka's Operating Cash Flow per Share too high?
Diagnostyka's current Operating Cash Flow per Share is €3.86. Based on the distribution chart, Diagnostyka ranks #54 out of 157 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnostyka has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's Operating Cash Flow per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #54 out of 157 companies for Operating Cash Flow per Share. This puts Diagnostyka in the upper half of its industry. The industry median Operating Cash Flow per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Diagnostics & Research company?
The median Operating Cash Flow per Share among Medical Diagnostics & Research companies is 13.10, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Diagnostyka and its competitors. For the Medical Diagnostics & Research industry, the median Operating Cash Flow per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current Operating Cash Flow per Share is €3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current Operating Cash Flow per Share of €3.86. The current Operating Cash Flow per Share is €3.86. Diagnostyka's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current Operating Cash Flow per Share is €3.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
26GF Score
Get the complete analysis for FRA:7JS
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
